Two-sided role of estrogen on endometrial carcinogenesis: stimulator or suppressor?

References

• Lortet-Tieulent J, Ferlay J, Bray F, et al. International patterns and trends in endometrial cancer incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354–361.
   PubMedGoogle Scholar
• Kamal A, Tempest N, Parkes C, et al. Hormones and endometrial carcinogenesis. Horm Mol Biol Clin Investig. 2016;25:129–148.
   PubMed Web of Science ®Google Scholar
• Yen SSC. The human menstrual cycle: neuroendocrine regulation. In Yen SSC, Jaffe RB, Barbieri RL, editors. Reproductive endocrinology. 4th ed. Philadelphia: WB Saunders Company; 1999. p. 191–197.
   Google Scholar
• Pettersson B, Bergström R, Johansson ED. Serum estrogens and androgens in women with endometrial carcinoma. Gynecol Oncol. 1986;25:223–233.
   PubMed Web of Science ®Google Scholar
• Nyholm HC, Nielsen AL, Lyndrup J, et al. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol. 1993;100:1115–1119.
   PubMedGoogle Scholar
• Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88:1127–1135.
   PubMed Web of Science ®Google Scholar
• Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84:975–981.
   PubMed Web of Science ®Google Scholar
• Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15:485–497.
   PubMed Web of Science ®Google Scholar
• Lépine J, Audet-Walsh E, Grégoire J, et al. Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways. J Clin Endocrinol Metab. 2010;95:2689–2698.
   PubMed Web of Science ®Google Scholar
• Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med. 2002;347:1593–1603.
   PubMed Web of Science ®Google Scholar
• Strauss III J, Coutifaris C. The endometrium and myometrium. Regulation and dysfunction. In Yen SSC, Jaffe RB, Barbieri R, editors. Reproductive endocrinology. 4th ed. Philadelphia: WB Saunders Company; 1999. p. 218–231.
   Google Scholar
• Hacker NF. Uterine cancer. In Berek JS, Hacker NF, editors. Practical gynecologic oncology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 397–410.
   Google Scholar
• Stanosz S, Żochowska E, Safranow K, et al. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. Metabolism. 2009;58:1–7.
   PubMed Web of Science ®Google Scholar
• Kraemer GR, Kraemer RR, Ogden BW, et al. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril. 2003;79:534–542.
   PubMed Web of Science ®Google Scholar
• Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7:522–525.
   PubMed Web of Science ®Google Scholar
• Cook CL, Siow Y, Brenner AG, et al. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141–146.
   PubMed Web of Science ®Google Scholar
• Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–5962.
   PubMed Web of Science ®Google Scholar
• Navaratnarajah R, Pillay OC, Hardiman P. Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med. 2008;26:62–71.
   PubMed Web of Science ®Google Scholar
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17.
   PubMed Web of Science ®Google Scholar
• Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001;91:22–26.
   PubMed Web of Science ®Google Scholar
• Lagarda H, Catasus L, Arguelles R, et al. K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol. 2001;193:193–199.
   PubMed Web of Science ®Google Scholar
• Palacios J, Catasus L, Moreno-Bueno G, et al. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch. 2001;438:464–469.
   PubMed Web of Science ®Google Scholar
• Li GM. DNA mismatch repair and cancer. Front Biosci. 2003;8:997–1017.
   PubMed Web of Science ®Google Scholar
• Kanaya T, Kyo S, Maida Y, et al. Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene. 2003;22:2352–2360.
   PubMed Web of Science ®Google Scholar
• Lynch HT, Snyder CL, Shaw TG, et al. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer. 2015;15:181–194.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Ando H, Asaka R, et al. Mutation analysis by whole exome sequencing of endometrial hyperplasia and carcinoma in one patient: abnormalities of polymerase epsilon and the phosphatidylinositol-3 kinase pathway. J Obstet Gynaecol Res. 2018;44:179–183.
   PubMed Web of Science ®Google Scholar
• Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res. 2000;60:235–237.
   PubMed Web of Science ®Google Scholar
• Ke H, Suzuki A, Miyamoto T, et al. 4-hydroxy estrogen induces DNA damage on codon 130/131 of PTEN in endometrial carcinoma cells. Mol Cell Endocrinol. 2015;400:71–77.
   PubMed Web of Science ®Google Scholar
• Liehr JG. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum Reprod Update. 2001;7:273–281.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Shiozawa T, Kashima H, et al. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology. 2006;147:4863–4870.
   PubMed Web of Science ®Google Scholar
• Niwa K, Morishita S, Murase T, et al. Chronological observation of mouse endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17 beta-estradiol. Cancer Lett. 1996;104:115–119.
   PubMed Web of Science ®Google Scholar
• Vilgelm A, Lian Z, Wang H, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 2006;66:3375–3380.
   PubMed Web of Science ®Google Scholar
• Jeong JW, Lee HS, Lee KY, et al. Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci USA. 2009;106:8677–8682.
   PubMed Web of Science ®Google Scholar
• Joshi A, Wang H, Jiang G, et al. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α. Am J Pathol. 2012;180:2536–2547.
   PubMed Web of Science ®Google Scholar
• Saito F, Tashiro H, To Y, et al. Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model. Int J Gynecol Cancer. 2011;21:1343–1349.
   PubMed Web of Science ®Google Scholar
• Zoubine MN, Weston AP, Johnson DC, et al. 2-methoxyestradiol-induced growth suppression and lethality in estrogen-responsive MCF-7 cells may be mediated by down regulation of p34cdc2 and cyclin B1 expression. Int J Oncol. 1999;15:639–646.
   PubMed Web of Science ®Google Scholar
• Nilsson ME, Vandenput L, Tivesten Å, et al. Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry. Endocrinology. 2015;156:2492–2502.
   PubMed Web of Science ®Google Scholar
• Asaka R, Miyamoto T, Yamada Y, et al. Elevated serum levels of estradiol induce endometrial hyperplasia rather than carcinoma in a mouse model using a carcinogen. J Carcinog Mutagen. 2017;8.
   Google Scholar
• Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575–580.
   PubMed Web of Science ®Google Scholar
• Bischoff J, Ignatov A, Semczuk A, et al. hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 2012;29:889–900.
   PubMed Web of Science ®Google Scholar
• Garg K, Shih K, Barakat R, et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009;33:1869–1877.
   PubMed Web of Science ®Google Scholar
• Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12:1071–1082.
   PubMed Web of Science ®Google Scholar
• Patel AV, Feigelson HS, Talbot JT, et al. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008;123:1877–1882.
   PubMed Web of Science ®Google Scholar